The Mitochondria Threshold

On CoQ10 and the delivery problem MitoQ solves

There is a threshold in every cell. Below a certain oxidative pressure, the mitochondria generate clean energy, repair damage, and sustain the conditions for the body to thrive. Above it, output drops, membrane integrity degrades, and the cell begins to run on deficit. How much pressure a mitochondrion can absorb before the picture changes is not fixed. It moves with age, with hormonal status, with chronic stress, with the accumulated terrain of life. What moves it downward, and what restores it, is the question the cellular longevity field is attacking with rigour.

MitoQ is impressively researched. It is also often misunderstood — partly because it is discussed as though it were simply an upgraded CoQ10 supplement, and partly because the mechanism that distinguishes it from every other antioxidant on the market is counterintuitive until you understand the architecture of the cell it is designed to reach.

The access problem

Coenzyme Q10 is endogenous. Every cell synthesises it. Its role in the electron transport chain — the mitochondrial machinery that converts nutrients into ATP — is foundational: it shuttles electrons between complexes I, II, and III, and in doing so enables the proton gradient that drives ATP production. Without sufficient CoQ10, the chain stalls, energy production drops and oxidative stress rises.

Synthesis begins declining in the mid-twenties, with the steepest drop occurring between 40 and 60. By later life, CoQ10 levels in cardiac tissue can be up to 50% lower than in our youth. Statin use accelerates this: statins block the mevalonate pathway, which is the same pathway used to synthesise CoQ10, so anyone on long-term statin therapy is depleting this substrate as a direct pharmacological consequence. High chronic stress increases demand. Perimenopause compounds the picture through the withdrawal of oestrogen, which has a direct mitochondrially protective role.

The supplementation logic, then, is straightforward: if the body's production is declining and demand is rising, exogenous CoQ10 should restore capacity. The delivery picture is more complicated.

The delivery problem is structural. CoQ10 is a large, lipophilic molecule. Standard oral CoQ10 — whether ubiquinone (the oxidised form) or ubiquinol (the reduced, active form) — is absorbed through the gut and circulates via lipoproteins in the bloodstream. What it cannot do efficiently is cross the double phospholipid membrane of the mitochondrion, which is where it is needed. The molecule reaches the vicinity of its target and stops at the gate.

Ubiquinol is better absorbed than ubiquinone and remains active longer in circulation. For general antioxidant benefit and systemic CoQ10 repletion, it is the superior choice. For protection at the site of ROS production — inside the mitochondrial matrix — both forms face the same structural constraint: neither crosses the inner membrane efficiently. Mitoquinol mesylate — MitoQ — was designed to solve that problem at the level of electrochemistry.

The architecture of targeted delivery

MitoQ is a synthetic compound. It bonds ubiquinol to a triphenylphosphonium cation — TPP+. That cation carries a permanent positive charge. Mitochondria maintain a strongly negative membrane potential across their inner membrane: approximately negative 180 millivolts. The cell generates this gradient as part of normal energy production. TPP+, being positively charged, is drawn through that gradient by simple electrochemistry, concentrating inside the mitochondrial matrix at levels estimated to be 100 to 1,000 times higher than circulating plasma concentrations. The ubiquinol travels with it.

The distinguishing factor is address — the ability to deliver an antioxidant to the precise compartment where mitochondrial oxidative damage originates, rather than releasing it into general circulation and hoping proximity does the work.

Once inside, MitoQ neutralises reactive oxygen species at the inner membrane before they oxidise mitochondrial DNA, damage respiratory chain proteins, or initiate membrane peroxidation. It is then oxidised to MitoQ+, recycled by the electron transport chain back to its active form, and available to act again. The mechanism replenishes itself in use.

The result, under conditions of elevated oxidative stress, is that MitoQ can scavenge superoxide and peroxynitrite directly at their point of production — the inner mitochondrial membrane — rather than intercepting them after they have already escaped into the cytoplasm. This is a different order of protection from what circulating antioxidants, including standard CoQ10, can offer.

The TPP+ question

Any honest account of MitoQ has to sit with the TPP+ carrier question. Triphenylphosphonium is a synthetic cationic compound. It accumulates in mitochondria by design and at sufficient concentration, it is capable of disrupting membrane potential. In vitro studies at concentrations far above physiological dosing have shown that TPP+ uncouples mitochondrial oxidative phosphorylation — disrupting the proton gradient that drives ATP production. That bears consideration: the same mechanism that delivers the antioxidant to the right address can, at high enough concentration, interfere with the cell's ability to make energy at all.

The distinction is concentration-dependence. At the doses used in human trials and consumer formulations (10mg per day, with some practitioners moving to 20mg), circulating TPP+ concentrations remain substantially below the threshold at which membrane disruption has been observed in cell studies. The compound is not retained permanently: if supplementation stops, mitochondrial accumulation reverses.

The gap that current research is closing is long-term human data. Trials to date have run for weeks to months rather than years. For anyone taking this compound now, that context matters. It argues for periodic reassessment — for treating MitoQ as a defined-window corrective intervention when oxidative load is elevated, with dosing reviewed as the terrain shifts.

This is the frame I use in practice with clients. MitoQ is appropriate when functional assessment indicates mitochondrial oxidative stress is a primary terrain issue. It is not a supplement for everyone, or for always. The mechanism that makes it effective is the same mechanism that makes thoughtful dosing and periodic review relevant.

The research trail

The published human research on MitoQ spans cardiovascular function, hepatic inflammation, exercise performance, cognitive markers, and vascular ageing. A 2018 randomised controlled trial in healthy late middle-aged and older adults showed a 42% improvement in endothelial function after six weeks at 20mg daily, with arterial stiffness also improving in participants who had elevated baseline levels. Studies in patients with Parkinson's disease, while inconclusive on primary motor endpoints, produced signals on secondary markers of oxidative stress. Research in chronic kidney disease showed reductions in mitochondrial dysfunction markers. The picture is not uniform across conditions, but the oxidative stress findings are consistent.

The most significant recent development in the MitoQ research picture is closer to home. In May 2026, NUS Medicine and MitoQ signed a formal research collaboration at the Singapore–New Zealand Leadership Forum, acknowledged by the New Zealand Prime Minister. The partnership is led by Associate Professor Jan Gruber at NUS Medicine's Healthy Longevity Translational Research Programme — who has previously run pre-clinical MitoQ studies — and it applies the LinAge3 biological ageing clock to evaluate MitoQ's efficacy.

LinAge3 measures biological age independently of chronological age and predicts long-term disease and mortality risk over 10- and 20-year horizons, and markers of physical and cognitive function. It is an algorithm-based tool that reads actual ageing trajectory, not proxy markers of a single metabolic pathway.

The research runs in two phases. The first, May to September 2026, analyses blood samples from an existing 150-person study using the LinAge3 clock. The second, beginning July 2026, is a controlled intervention trial with approximately 100 participants, combining epigenetic clocks, vascular and cognitive markers, and multi-layer molecular blood analysis. Completion is expected December 2027.

What this methodology represents is a shift in the quality of question being asked. Previous MitoQ studies have measured whether it reduces a specific oxidative stress marker. The NUS research is asking whether it measurably alters how fast a body ages.

Perimenopause

Oestrogen is mitochondrially protective — upregulating proteins involved in mitochondrial biogenesis, exerting direct antioxidant effects within the mitochondrial membrane, and supporting Complex I and Complex IV activity in the electron transport chain. Much of this is mediated by oestrogen receptor beta, which is expressed in mitochondria themselves. When oestrogen declines in perimenopause, the downstream effect is a simultaneous slowing of biogenesis, increased membrane vulnerability, and rising ROS production as the electron transport chain becomes less efficient.

What many women experience in this transition — the fatigue that arrives mid-afternoon and does not resolve with sleep, the loss of exercise recovery, the brain fog that feels like the signal has been muffled — is consistent with declining mitochondrial output. The hormonal narrative rarely reaches this layer. The conversation stays at the symptom surface: hot flushes, mood disruption, sleep fragmentation. The cellular floor beneath those symptoms remains unaddressed.

Progesterone has a complementary protective role. It supports mitochondrial function and reduces neuroinflammation. Its decline in perimenopause — which typically precedes oestrogen decline and is more variable — compounds the mitochondrial load. The combined effect is a progressive reduction in the cell's capacity to produce clean energy and manage oxidative stress.

For women in this transition, MitoQ acts directly on the oxidative stress that oestrogen withdrawal leaves unmanaged — scavenging ROS at the inner membrane where the hormonal protection has thinned. It does not replace hormonal support where that is indicated; it works on a distinct and simultaneous layer.

MitoQ in the cellular longevity framework

The Cellular Energy Terrain is the architecture beneath the nine domains of my Total Load framework. It is where mitochondrial function, mitophagy, NAD+ availability, and cellular antioxidant status interact to determine how efficiently a cell converts input to output — and how quickly it degrades under pressure.

Assessing that terrain requires markers that speak to oxidative stress directly. Three are worth considering: GGT — gamma-glutamyl transferase, typically dismissed as a liver marker — is one of the most sensitive indicators of oxidative burden and mitochondrial stress available through standard blood panels; optimal sits below 15 U/L, and anything above 25 warrants attention. hs-CRP below 0.5 mg/L indicates low inflammatory load; above 3.0, inflammatory burden is elevated and mitochondrial ROS is likely among the contributing drivers. Fasting insulin between 2 and 5 µIU/mL reflects metabolic efficiency at the cellular level; chronically elevated insulin is a direct mitochondrial stressor. These markers are accessible, affordable, and available through standard and preventive medicine and longevity clinics.

Beyond blood, VO2 max is arguably the most meaningful functional measure of mitochondrial capacity in the body. It reflects how efficiently the entire system — cardiac output, oxygen delivery, mitochondrial extraction — converts effort to energy. For women aged 50–59, above 35 ml/kg/min is excellent; below 22 indicates low mitochondrial reserve. It can be measured at exercise physiology centres in any city.

Three interventions operate on this terrain with distinct roles. MitoQ addresses mitochondrial oxidative stress: the scavenging of ROS at the inner membrane before they damage the machinery. Urolithin A addresses mitochondrial quality control: the selective clearance of damaged mitochondria via mitophagy, making way for biogenesis of healthy replacements. NAD+ precursors — NMN and NR — address the substrate layer: replenishing the cofactor that powers the sirtuin and PARP pathways, which regulate mitochondrial biogenesis, DNA repair, and metabolic adaptation.

Each targets a different layer of the same system, and combining them without first establishing which layer is the primary constraint wastes resources and adds variables to a system that benefits from clarity about where the bottleneck sits.

MitoQ is most appropriate when oxidative stress load is the primary terrain issue — when markers like GGT and hs-CRP indicate the mitochondrial membrane is absorbing more ROS than the endogenous antioxidant system can manage. When the primary issue is mitochondrial quality — a high proportion of damaged, inefficient mitochondria — mitophagy support becomes the first priority. When NAD+ depletion is driving low cellular energy output, substrate replenishment takes precedence.

The question is never which of these is best in the abstract. It is which mechanism the specific terrain requires, in what sequence, and at what dose — and that requires functional assessment, not inference from symptoms.

The question is always which mechanism the specific terrain requires, in what sequence, and at what dose — and the answer requires functional assessment.

My experience

I began taking MitoQ at the standard consumer dose: two capsules, fasted, in the morning. I was interested in the mechanism and had the context to evaluate whether I was experiencing any effect.

What functional assessment subsequently showed was a picture inconsistent with effective mitochondrial antioxidant activity — GGT and inflammatory markers that should have moved more than they had at standard dose. My practitioner's read was that I was either a poor absorber or that my oxidative load was high enough to require more than the consumer formulation could deliver. The recommendation was to move to the 20mg practitioner formulation, or to double the consumer dose.

What I noticed after moving to the higher dose, over several weeks, was a shift in the back end of a full week. The particular cellular fatigue — distinct from sleep debt, arriving when the system has been running hard and needs a floor to rest on — had diminished. Recovery from physical output settled faster. These are not dramatic signals. They are the kind of signals you notice only if you have been paying attention to the right register, and if you have a baseline clear enough to detect the difference.

The science told me what to look for, and the experience bore it out.

What this means in practice

MitoQ earns its place in a cellular longevity protocol when the terrain warrants it. The mechanism is well-characterised, the research trail is substantive, and the NUS collaboration represents a meaningful step toward the quality of evidence this space has needed.

The caveats are equally substantive. TPP+ accumulation at high doses warrants attention. Long-term continuous use has not been studied in humans at the depth that would satisfy rigorous safety standards. Standard consumer dosing may be insufficient for individuals with elevated oxidative load or compromised absorption. These considerations argue for taking MitoQ with assessment, with a clear rationale, and with periodic review as the terrain changes.

The broader cellular longevity picture — mitochondrial oxidative stress addressed by MitoQ, mitophagy addressed by Urolithin A, NAD+ substrate addressed by NMN or NR — is a coherent framework. Each mechanism is distinct. Each has a place. It is worth noting that MitoQ's most consistent research signal is in recovery — from exercise, from travel, from high-demand weeks — rather than dramatic increases in baseline ATP output. That is what the personal experience section reports. The work is identifying which mechanism the individual terrain requires, in what sequence, and with what dose.

The practitioner-grade compound is only available through qualified practitioners. For those wanting to understand whether the 20mg formulation is appropriate for their terrain, the conversation starts with a functional assessment of what your cellular terrain looks like before deciding what to build on it.

Does it raise your E?

E is energy, vitality, capacity — the governing question of my MC²L framework, applied to every intervention, food, environment, and decision that enters the picture. For MitoQ, at the right dose, for the right terrain, tracked with the right tools: yes.

FRAMEWORK NOTE

MitoQ sits within the Cellular Energy Terrain, the sub-cellular architecture of my Total Load framework. The nine scored domains of the Total Load Inventory map where the mitochondrial floor is set and what the terrain actually requires. Interventions applied without this map are applied blind.

The Total Load Audit is a 90-minute diagnostic session that produces a scored Total Load Map. For enquiries →

Michelle Saram is a Regenerative Living Architect and founder of Michelle Clean × Conscious Living — a physiology-first regenerative health platform built around the Total Load Concept. Health questions should be directed to qualified integrative or functional medicine practitioners. This essay reflects Michelle's framework and personal experience. It is not medical advice.